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Introduction
Preeclampsia is a complication of pregnancy character-
ised by maternal hypertension and proteinuria that is asso-
ciated with significantly increased maternal and neonatal 
morbidity and mortality. There is evidence that women 
with a history of preeclampsia or eclampsia exhibit an 
increased cardiovascular comorbidity.1 Vascular endothe-
lial dysfunction plays an important role in the pathogene-
sis of this disease,2 and impaired uteroplacental circulation 
indicated by increased impedance to flow, notching or 
foetal growth restriction is a putative precursor to preec-
lampsia.3 An involvement of insulin resistance, dyslipi-
daemia, and inflammation in the pathogenesis of 
preeclampsia is well documented.4 Recently, prolonged 
elevations of plasma C-reactive protein (CRP) levels up to 
30 years after a preeclamptic pregnancy have been 
described.5 Other groups reported that elevated CRP 
levels are a risk factor for preeclampsia.6,7 Furthermore, 
there is some evidence that CRP levels are associated with 
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Abstract
Introduction: Disturbance of the uteroplacental circulation (UPC) and the renin-angiotensin system are involved in 
the pathogenesis of preeclampsia. In women with history of preeclampsia persistently elevated C-reactive protein (CRP) 
levels have been described. The angiotensin-converting enzyme (ACE) intron 16 insertion/deletion (I/D) genotype is 
associated with ACE activity and assumed to be a risk factor for preeclampsia. As ACE generates proinflammatory 
angiotensin II, we analysed, whether ACE intron 16 I/D genotype is associated with CRP and whether this association 
exhibited a relation to uteroplacental dysfunction.
Materials and methods: A total of 639 women have been followed during pregnancy with repeated measurements 
of CRP levels (observations: n=2333). ACE intron 16 I/D genotype was determined, and its association with CRP was 
assessed with adjustment for non-independent observations.
Results: CRP levels of ACE D allele carriers were significantly higher than those of the ACE II (wild-type) genotype 
(p=0.0003, padj=0.04). This relation was allele-dose dependent (p<10−4, padj<0.02). Association between ACE I/D and CRP 
was significantly restricted to patients presenting with impaired UPC in univariate (p<0.04) and multivariate analyses (p=0.01).
Conclusions: The ACE I/D genotype is significantly associated with CRP elevations during pregnancies complicated by 
disturbed UPC. Whether this effect on CRP is involved in pathogenesis of preeclampsia has to be elucidated.
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severity of preeclampsia8 and that variants in the CRP 
gene are associated with risk of preeclampsia.9 However, 
a relationship between CRP levels and preeclampsia could 
not be corroborated in all studies on this topic (e.g.10) and 
there are some data that indicate that the relation between 
CRP and preeclampsia is modified by confounders like 
weight status.7 Finally, it is assumed that the renin-angio-
tensin-aldosterone system (RAAS) is part of a pathway 
implicated in the pathogenesis of preeclampsia.11,12 In this 
context, the intron 16 insertion/deletion (I/D) genotype of 
the angiotensin converting enzyme (ACE) is discussed as 
a potential genetic risk factor for preeclampsia with some 
studies supporting such an association as well as others 
that indicate a null association.13–16 Carriers of the ACE 
intron 16 D allele are assumed to exhibit higher plasma 
ACE activities as compared to individuals with the ACE 
intron 16 II (wild-type) genotype.17 As angiotensin II, 
which is generated from angiotensin I by an ACE depend-
ent reaction, is known as a mediator of inflammation,18 
we hypothesised that the ACE intron 16 I/D genotype 
could be associated with plasma CRP levels, which in part 
could explain the relation between elevated CRP levels 
and history of preeclampsia. Based on these results, we 




We studied the association of the ACE intron 16 I/D geno-
type with plasma CRP levels in 639 consecutive pregnant 
women presenting in our haemostaseologic outpatient unit 
for medical attendance during pregnancy due to thrombo-
philia, history of venous thromboembolism, and/or history 
of foetal loss. Information on uteroplacental circulation 
was available in 476 patients. Of these, 76 presented with 
signs of uteroplacental insufficiency in uteroplacental 
Doppler ultrasound examination indicated by high imped-
ance to flow, notching, and/or foetal growth restriction. 
Patients were followed up to 12 weeks after delivery. The 
median interval between consecutive CRP measurements 
was 36 days (interquartile range (IQR): 31–43 days). As 
CRP levels are critically influenced by a multitude of envi-
ronmental factors, which are nearly uncontrollable, we 
used a time-averaged approach including all CRP measure-
ments and adjusted for non-independent observations.19 
Analyses were performed on 639 patients with a total of 
2333 CRP measurements (number of presentations: one 
(n=72), two (n=147), three (n=103), four (n=98), more than 
four (n=219)). Five hundred and sixty-five patients (88%) 
were of German origin and the other women were of 
Middle East and Asian origin. The study was approved by 
the local ethics committee, and the patients were enrolled 
after giving informed consent.
Genotyping and CRP measurements
The ACE intron 16 I/D genotypes were characterised by 
amplification fragment length polymorphisms, as described 
previously.20 Briefly, after extraction of genomic DNA 
from whole blood using GenoPrep Cartridges B and the 
GenoM-6 system (GenoVision, Vienna, Austria), a primer 
pair consisting of 5’GAC CTG CTG CCT ATA CAG T 3’ 
and 5’GGG TAA AAC TGG AGG ATG GCT C 3’ was used 
for amplification, generating a 234 bp product for the ACE 
intron 16 deletion allele, and a 521 bp amplification prod-
uct for the ACE intron 16 insertion allele. Additionally, the 
primer pair 5’GAT TAC AGG CGT GAT ACA GT 3’ and 
5’GGG TAA AAC TGG AGG ATG GCT C 3’, which is 
specific for the ACE intron 16 insertion allele, was used. 
All primers were synthesised by TIB Molbiol (Berlin, 
Germany). Plasma CRP levels were quantified by an immu-
noturbidimetric method standardised according to the 
International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) with a lower detection limit 
of 3 mg/l (Roche Diagnostics, Germany).21
Statistical analyses
The ACE intron 16 I/D genotype was assessed by the 
Pearson χ2 test to determine if the observed genotype distri-
bution was in accordance to expected Hardy-Weinberg 
proportions.
Nonparametric comparisons of CRP levels between the 
different ACE intron 16 I/D genotype combinations were 
done by Mann-Whitney U test or in the case of allele-dose 
dependency by the Cuzick nonparametric test for trend. 
For univariate analyses on the association between ACE 
intron 16 I/D genotype and CRP elevations above 10 mg/l, 
odds ratios (ORs) and exact 95% confidence intervals 
(95% CIs) were calculated. For calculations on allele-dose 
dependency, the ACE intron 16 II genotype was used as 
reference group, and a test for linear trend of the log odds 
(trend test) was performed. For multivariate analyses, ORs 
and 95% CIs were calculated by a logistic regression 
model adjusting for age (quartiles), weeks of gestation 
(≤12 weeks, 13–24 weeks, and >24 weeks), ethnicity, and 
body mass index (BMI) (>25 kg/m2).
As CRP levels are influenced by a multitude of 
uncontrollable environmental factors, we decided to use 
a time-averaged approach. Several CRP measurements 
per patient have been included in the analyses. Even 
though, the usage of clustered data not necessarily 
biases statistical analyses, intracluster correlation has to 
be considered and statistically assessed. Consequently, 
adjustments for non-independent observations within 
clusters have been performed (padj) for all analyses, as 
described previously.19 These adjustments relax the 
independence assumption so that independence is only 
required across clusters.22
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All statistical analyses were performed using Stata 
Statistical Software for Macintosh, release 10.1 (StataCorp, 
USA).
Results
In the study population, the frequencies of the different 
ACE intron 16 I/D genotypes were: 25.2% for ACE intron 
16 II, 49.3% for ACE intron 16 ID, and 25.5% for ACE 
intron 16 DD. The determined genotype distribution in this 
cohort was consistent with Hardy-Weinberg equilibrium 
(p=0.72). Further characteristics of the study population 
are given in Table 1. Briefly, patients with disturbed utero-
placental circulation (UPC) exhibited a significantly 
higher BMI when compared with those with normal UPC. 
Furthermore, fibrinogen levels were significantly higher in 
case of disturbed UPC (Table 1).
The mean CRP level in the total study population was 
5.5 mg/l (Table 2). When comparing the CRP levels 
depending on the women’s ethnicity, there was a highly 
significant difference (padj=0.0003). While in women of 
German origin the mean CRP level was 5.5 mg/l (95% CI: 
5.2–5.7), in women of other ethnicities it was considerably 
higher (6.2 mg/l, 95% CI: 5.7–6.7).
The comparison of CRP levels depending on presence 
or absence of the ACE intron 16 D allele revealed signifi-
cantly higher CRP levels in carriers of the ACE intron 16 
D allele (p=0.0003). After adjustment for non-independent 
observations, the difference in CRP levels between ACE D 
allele carriers and non-carriers was statistically significant 
(padj=0.04), as well. Subsequently, we tested, whether CRP 
levels depend on the number of ACE intron 16 D alleles. 
The differences in mean plasma CRP levels between the 
different ACE intron 16 I/D genotypes were moderate 
(Table 2). However, the statistical assessment indicated a 
significant increase in CRP levels with ascending numbers 
of ACE intron 16 D alleles without and with adjustment 
for non-independent observations (p<10−4, padj<0.02) 
(Table 2).
In patients with disturbed UPC, the mean CRP level 
tended to be higher (6.1 mg/l, 95% CI: 5.1–7.1) than in 
those presenting with normal uteroplacental function (5.5 
mg/l, 95% CI: 5.2–5.7) (p=0.02, padj=0.14). When perform-
ing the analyses on the association of the ACE intron 16 I/D 
genotype with CRP levels stratified by the absence or pres-
ence of uteroplacental dysfunction, there was only a small 
increase in mean CRP levels with increasing numbers of 
ACE intron 16 D alleles in normal UPC (II: 5.2 mg/l, ID: 
5.2 mg/l, DD: 6.0 mg/l), while this relation was considera-
bly more pronounced in those patients with disturbed UPC 
(II: 4.5 mg/l, ID: 5.7 mg/l, DD: 8.8 mg/l) (Table 2). When 
restricting these analyses on patients with Caucasian origin 
the results remained essentially unchanged. Mean CRP lev-
els increased with the number of ACE intron 16 D alleles 
(p<10−3/padj<0.04) and this effect was especially prominent 
in Caucasian patients with disturbed UPC (II: 4.6 mg/l, ID: 
5.7 mg/l, DD: 8.8 mg/l). Mean CRP levels tended to be dif-
ferent between Caucasian patients without (5.4 mg/l, 95% 
Table 1. Characteristics of the study population.
Characteristics Total Normal UPC Disturbed UPC
Age (years), median (IQR) 32 (28–36) 32 (28–36) 33 (28–35)
BMI, median (IQR) kg/m2 23.6 (21.5–26.9) 22.7 (21.0–25.3)a 26.0 (23.7–28.7)a
Fbg, mean (95% CI) g/l 4.53 (4.47–4.59) 4.49 (4.42–4.55)b 4.80 (4.63–4.98)b
DD, mean (95% CI) mg/l 0.24 (0.22–0.25) 0.23 (0.22–0.24) 0.27 (0.23–0.31)
BMI: body mass index; CI: confidence interval; CRP: C-reactive protein; DD: D-dimer concentration; Fbg: fibrinogen concentration; IQR: interquar-
tile range; p: p-value for nonparametric comparison; padj: p-value after adjustment for non-independent observations; UPC: uteroplacental circulation.
ap<10−4; bp<10−3/padj=0.007.
Table 2. Plasma levels of C-reactive protein (CRP) in dependence of the angiotensin-converting enzyme (ACE) intron 16 insertion/
deletion genotype and uteroplacental dysfunction.









5.5 (5.3–5.8) 5.2 (4.7–5.7) 5.4 (5.1–5.8) 6.0 (5.5–6.5) <10−4 /<0.02
Normal UPC 5.2 (4.7–5.7) 5.2 (4.8–5.6) 6.0 (5.6–6.5) <0.001 / 0.05
(n=400)  
Disturbed UPC 4.5 (3.8–5.1) 5.7 (5.0–6.4) 8.8 (4.7–12.9) 0.007 / 0.10
(n=76)  
P, P-value for nonparametric comparison of CRP levels. Padj, P-value after adjustment for non-independent observations.
CRP, C-reactive protein; ACE, angiotensin converting enzyme; I, insertion polymorphism; D, deletion polymorphism; CI, confidence interval; UPC, 
uteroplacental circulation.
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CI: 5.1–5.7) and with disturbed UPC (6.1 mg/l, 95% CI: 
5.0–7.2) (p=0.006, padj=0.10).
Carriage of the ACE intron 16 D allele tended to be 
associated with CRP elevations above twice the normal 
range (≥10 mg/l, OR: 1.36, 95% CI: 0.98–1.92) (Table 3). 
When considering the allele-dose, there was a significant 
trend towards CRP elevations with increasing number of 
ACE intron 16 D alleles (II: reference; ID: OR: 1.23, 95% 
CI: 0.87–1.73; DD: OR: 1.61, 95% CI: 1.12–2.32; p for 
trend <0.009). Interestingly, when stratifying for normal 
and disturbed UPC, a clear heterogeneity between both 
strata in respect of the relation of ACE intron 16 I/D geno-
type and CRP elevations could be found (Table 3). In nor-
mal UPC, no association between CRP elevations and 
either ACE intron 16 D allele carriage or number could be 
detected in univariate and multivariate analyses. On the 
other hand, in patients with disturbed UPC there was a sig-
nificant association of ACE intron 16 D allele carriage 
(OR: 5.34, 95% CI: 1.27–47.6) and copy number (II: refer-
ence; ID: OR: 4.38, 95% CI: 1.08–17.7; DD: OR: 7.84, 
95% CI: 1.98–31.0; p for trend=0.004) (Table 3). When 
restricting these analyses on patients with Caucasian ori-
gin the results remained essentially unchanged.
The findings could be confirmed in multivariate analy-
ses adjusting for possible confounders including body 
mass index and ethnicity. The heterogeneity between both 
strata defined by normal and disturbed UPC, respectively, 
in respect of the association of ACE intron 16 I/D geno-
type and CRP was statistically significant in univariate 
(p<0.04, padj<0.05) as well as multivariate analyses 
(p=0.01, padj=0.03).
Discussion
Based on the interrelationship between inflammation, 
RAAS, uteroplacental disturbance and preeclampsia we 
investigated, whether (a) there is a relation between the 
ACE intron 16 I/D genotype and plasma CRP levels during 
pregnancy and (b) whether this relation is affected by uter-
oplacental function. We tested this hypothesis in a cohort 
of pregnant women. There is evidence that pregnancy 
itself could be considered as an inflammatory stressor,23 
which translates in elevations of plasma CRP levels even 
during normal pregnancy.24 Thus, we tested our hypothesis 
in a population under slightly proinflammatory conditions. 
In our cohort, the mean CRP level was 5.5 mg/l, which is 
in good agreement with the results of a recent study on 
CRP levels during pregnancy.23 When comparing patients 
without and with disturbed UPC there was a trend towards 
higher CRP levels in patients with disturbed UPC that did 
not reach statistical significance. Due to the relatively 
small sample size and the fact that we used a non high-
sensitivity CRP quantification technique in patients with 
only moderate inflammatory stimulation, our results might 
underestimate the relation between UPC disturbance and 
CRP levels.
In our study population a highly significant heterogene-
ity in CRP levels depending on the ethnicity could be rec-
ognized (padj=0.0003), a finding, which has been described 
previously.23 Due to this heterogeneity our statistical 
approaches comprised univariate analyses restricted on 
patients with Caucasian origin as well as multivariate anal-
yses, which were adjusted for ethnicity.
In the present study, we could identify a statistically 
significant association between the ACE intron 16 I/D 
genotype and plasma CRP levels. This relation was allele-
dose dependent. Most interestingly, this association was 
significantly restricted on patients presenting with dis-
turbed uteroplacental function as evidenced by high 
impedance to flow, notching and/or foetal growth restric-
tion (Table 3). The influence of the ACE intron 16 I/D 
genotype on CRP levels, which we describe, was modest, 
Table 3. Association of the angiotensin converting enzyme intron 16 insertion/deletion (I/D) genotype with C-reactive protein 
(CRP) in dependence on uteroplacental dysfunction.
CRP <10 mg/l versus ≥10 mg/l
 Total Uteroplacental circulation




Carriage of ACE D allele  
Univariate 1.36 (0.98–1.92) 1.11 (0.76–1.64)† 5.34 (1.27–47.6)†
Multivariate 0.86 (0.51–1.45) 0.61 (0.33–1.10)‡ 6.06 (1.11–33.1)‡
Trend test  
ACE II 1 (reference) 1 (reference) 1 (reference)
ACE ID 1.23 (0.87–1.73) 0.91 (0.61–1.36) 4.38 (1.08–17.7)
ACE DD 1.61 (1.12–2.32) 1.47 (0.97–2.22) 7.84 (1.98–31.0)
Results of χ2 testing, multivariate analyses (adjusted for age, weeks of gestation, ethnicity, and body mass index), and trend tests are presented.
†Test of homogeneity between strata defined by normal and disturbed UPC, p<0.04, padj<0.05.
‡Test of homogeneity between strata defined by normal and disturbed UPC, p=0.01, padj=0.03.
CRP, C-reactive protein; ACE, angiotensin converting enzyme; OR, odds ratio; CI, confidence interval; UPC, uteroplacental circulation.
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which again could be due to the usage of a non-highly sen-
sitive CRP quantification technique presumably resulting 
in an underestimation of the effect of the ACE intron 16 
I/D genotype on the CRP concentration. Furthermore, the 
results of our study derive from a cohort of pregnant 
women, thus, it has to be tested, whether our results could 
be translated to other inflammatory conditions. There are a 
few other published studies investigating the relation 
between ACE intron 16 I/D genotype and CRP level. 
Bahramali and co-workers studied this relation in patients 
with coronary artery disease and they did not find any evi-
dence of an association between this ACE polymorphism 
and CRP levels.25 In another study, this relation was tested 
in patients suffering from advanced cancers.26 In this study 
population a trend towards higher CRP levels in carriers of 
the ACE intron D allele was found, however, without 
reaching statistical significance. The absence of a detecta-
ble relation between ACE intron 16 I/D genotype and CRP 
level in these studies could be related to small sample 
sizes. In respect of the cohort with coronary artery disease 
another possible explanation could be related to a low pro-
inflammatory stimulus in these patients. However, it can-
not be excluded that the findings of our study are due to 
other mechanisms specific for uteroplacental dysfunction.
There are some details, which argue for a true associa-
tion between ACE intron 16 I/D genotype and CRP levels 
in patients with disturbed uteroplacental function. Firstly, a 
considerable influence of the ACE intron 16 I/D genotype 
on the serum ACE activity has been described, with increas-
ing serum ACE levels with ascending numbers of the ACE 
intron 16 D allele.17 Several other groups could replicate 
these findings.13 As ACE converts angiotensin I to angio-
tensin II, which itself exerts proinflammatory effects,18 the 
relation of the ACE intron 16 I/D genotype to CRP levels 
could be mediated by this part of the RAAS pathway. This 
hypothesis is corroborated by another recent report, which 
described a significant reduction of plasma CRP levels 
under the treatment with ACE inhibitors.27 Secondly, in our 
study a clear allele-dose dependency of the relation between 
ACE intron 16 I/D genotype and CRP (Tables 2 and 3) 
could be identified. This fact argues against a finding medi-
ated by possible uncontrolled confounders. Finally, the sta-
tistically significant heterogeneity between women without 
and with uteroplacental insufficiency argues against an 
association, which is primarily mediated or biased by preg-
nancy or pregnancy-related changes, and it is clearly com-
patible with an involvement of the RAAS and the ACE 
intron 16 I/D genotype in some aspects of pathogenesis of 
uteroplacental insufficiency and preeclampsia. However, 
this assumption as well as the transferability of the relation 
between the ACE intron 16 I/D genotype and CRP to other 
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